Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Osteopore Ltd. ( (AU:OSX) ) has provided an update.
Osteopore Limited has signed an exclusive 15-year licensing agreement with Accelerate Technologies, the commercialisation arm of Singapore’s A*STAR, to use a Heparan Sulphate bioactive technology platform designed to significantly accelerate bone and tissue regeneration when combined with Osteopore’s existing implant technology. The licence, which includes patents and know-how for two Heparan Sulphate families such as HS3 and covers all life science, medical, research and clinical uses across key global markets, positions Osteopore to access the fast-growing bone morphogenetic protein-2 (BMP-2) market in Asia-Pacific, valued at USD 670 million in 2024 and forecast to expand at 8.5% annually, although the company does not expect a short-term material impact on earnings as clinical trials and regulatory milestones progress.
The most recent analyst rating on (AU:OSX) stock is a Hold with a A$0.01 price target. To see the full list of analyst forecasts on Osteopore Ltd. stock, see the AU:OSX Stock Forecast page.
More about Osteopore Ltd.
Osteopore Limited is an Australian-Singaporean regenerative medicine company and global leader in 3D-printed biomimetic and bioresorbable implants, focused on bone and tissue regeneration solutions for clinical applications across major markets including the United States, European Union and China.
Average Trading Volume: 526,577
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$1.77M
For an in-depth examination of OSX stock, go to TipRanks’ Overview page.